NeOnc Technologies (NTHI) vs ProMIS Neurosciences (PMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ProMIS Neurosciences (PMN) has outperformed NeOnc Technologies (NTHI) over the past year, losing 35.8% versus a loss of 79.1%. ProMIS Neurosciences is the larger company by market cap ($82.1 million vs $72.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NTHI | PMN |
|---|---|---|
| Share price | $2.53 | $9.15 |
| Market cap | $72.88M | $82.05M |
| 1-day change | -6.64% | +0.33% |
| YTD return | -69.41% | +33.97% |
| 1-year return | -79.07% | -35.79% |
| 5-year return | — | -95.93% |
| EPS (TTM) | $-2.13 | $-11.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.09 | $27.40 |
| 52-week low | $2.52 | $6.27 |
| Distance from 52-week high | -79.07% | -66.61% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +571.94% | +365.68% |
| Average volume | 195.17K | 84.01K |
| Shares outstanding | 28.81M | 8.97M |
| Employees | 5 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PMN has outperformed NTHI by 43.3 percentage points over the past year.
About NeOnc Technologies
NTHI stock →NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About ProMIS Neurosciences
PMN stock →ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
NTHI vs PMN FAQ
Which is bigger, NeOnc Technologies or ProMIS Neurosciences?
ProMIS Neurosciences (PMN) is larger, with a market capitalization of $82.05M compared with $72.88M for NeOnc Technologies (NTHI).
Which stock has performed better over the past year, NTHI or PMN?
PMN returned -35.79% over the past 12 months, compared with -79.07% for NTHI (price return, excluding dividends). Past performance does not predict future results.
Are NeOnc Technologies and ProMIS Neurosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.